RETINA VITREOUS ASSOCIATES MEDICAL GROUP
NPI: 1134164023
· LOS ANGELES, CA 90017
· 174400000X
$24.03M
Total Medicaid Paid
Monthly Spending Trend
Yearly Breakdown
| Year | Claims | Total Paid |
|---|
| 2018 |
49,194 |
$1.97M |
| 2019 |
57,390 |
$2.92M |
| 2020 |
51,410 |
$3.29M |
| 2021 |
54,569 |
$3.69M |
| 2022 |
56,463 |
$3.92M |
| 2023 |
71,167 |
$4.62M |
| 2024 |
61,340 |
$3.61M |
Billing Codes
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 67028 |
|
63,561 |
59,754 |
$6.80M |
| J0178 |
Aflibercept injection |
10,788 |
10,386 |
$5.41M |
| 92014 |
|
66,728 |
64,703 |
$2.91M |
| 92134 |
|
121,247 |
115,255 |
$1.76M |
| J9035 |
Bevacizumab injection |
31,518 |
29,577 |
$1.69M |
| Q5128 |
Inj, cimerli, 0.1 mg |
4,699 |
4,551 |
$1.59M |
| 92012 |
|
34,024 |
32,510 |
$1.47M |
| J2778 |
Ranibizumab injection |
1,697 |
1,643 |
$634K |
| J2777 |
Inj, faricimab-svoa, 0.1mg |
872 |
847 |
$448K |
| 99204 |
|
6,924 |
6,920 |
$289K |
| 92202 |
|
21,525 |
21,163 |
$161K |
| 92235 |
|
5,410 |
5,072 |
$161K |
| 92226 |
|
10,508 |
6,007 |
$139K |
| J3490 |
Drugs unclassified injection |
286 |
264 |
$128K |
| 92250 |
|
6,581 |
6,530 |
$91K |
| J7999 |
Compounded drug, noc |
2,776 |
2,645 |
$76K |
| 76512 |
|
2,524 |
2,067 |
$63K |
| 92004 |
|
2,034 |
2,032 |
$61K |
| 99214 |
|
1,612 |
1,564 |
$54K |
| 92225 |
|
2,161 |
1,192 |
$26K |
| J2781 |
Inj, pegcetacoplan, 1mg |
43 |
42 |
$20K |
| 92201 |
|
2,340 |
2,333 |
$19K |
| 67228 |
|
95 |
91 |
$14K |
| J0177 |
Inj, aflibercept hd, 1 mg |
14 |
14 |
$8K |
| 99024 |
|
1,402 |
1,174 |
$5K |
| 99213 |
|
126 |
124 |
$3K |
| J3300 |
Triamcinolone a inj prs-free |
24 |
12 |
$584.08 |
| 76510 |
|
14 |
13 |
$384.10 |